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More than 6 million confirmed cases of COVID-19 (coronavirus disease 2019) have been identified
worldwide and a number of case reports1-5 have indicated that COVID-19 has the potential to be
transmitted prior to disease onset. Studies have also shown that infectious virus can be isolated from
presymptomatic COVID-19 cases6 and although it is unknown what level of infectious virus is needed to
confer efficient transmission potential, detection of infectious virus in the upper respiratory tract indicates
that presymptomatic transmission of COVID-19 is plausible. Fear of asymptomatic and presymptomatic
transmission of COVID-19 has led to considerable concern among public health policy makers, frontline
healthcare workers and the public in general. In response, many city, state, and federal leaders have
asked for increased testing via reverse transcriptase-polymerase chain reaction (RT-PCR) and
serological assays in order to identify asymptomatic cases and potential spreaders. Individual case
studies are important for bringing attention to this topic but they do not provide information regarding the
overall proportion of transmission events that occur before or after symptom onset. A better
understanding of COVID-19 transmission is needed to control this pandemic and although some recent
studies have provided new insight, others have fueled increased concerns.

Recent modeling of 77 transmission pairs indicated that 34 instances (44%) of COVID-19 transmission
occurred before symptom onset with peak transmission at 0.7 days before symptom onset7. This is an
unusual outcome because most respiratory viruses, including influenza or Severe Acute Respiratory
Syndrome Coronavirus (SARS-CoV), spread most efficiently at or after symptom onset and not before.
There are also several limitations to this study. The model was not based on direct contact tracing but
instead relied upon publicly available data sources and news media reports for determining
presymptomatic vs. post-symptomatic exposures and transmission intervals. The authors noted that
they used a previously published estimate of the COVID-19 incubation period that, if overestimated, had
the potential to inflate the proportion of presymptomatic transmission. Sensitivity analysis of different
incubation periods is currently underway (M.K. Slifka, L. Gao, unpublished data, 6/01/2020). Regardless
of the study, clinical data based on personal recollection may be subject to recall bias. This may be

Page 2 of 7

particularly important for COVID-19 transmission models if subjects are reluctant to admit they were
travelling or not following proper precautions while symptomatic due to pandemic-associated societal
pressure and fear of condemnation for their actions. Although it is unclear how these various factors
may have impacted this particular study, review of other COVID-19 and SARS transmission studies
provide an interesting counterpoint.

In contrast to He et al.7, a study examining 468 confirmed COVID-19 cases in China indicated that only
59 (12.6%) of case reports resulted from presymptomatic transmission8. Although this study was also
based on secondary data sources, they obtained reliable information from confirmed cases in online
reports from 18 provincial centers for disease control and prevention. Perhaps the most convincing study
on presymptomatic transmission of COVID-19 was performed in Singapore9. Direct contact tracing of
157 locally acquired cases indicated that just 10 (6.4%) of the cases occurred through presymptomatic
transmission. Together these studies indicate COVID-19 transmission is 10- to 20-fold more efficient
after symptom onset.

Asymptomatic transmission raises similar concerns for contact tracing/isolation procedures, but a study
of 24 asymptomatic cases of COVID-19 found that only one asymptomatic carrier transmitted the virus to
another person10. Bearing in mind that COVID-19 has a reproductive number (R0) = 2-3 (meaning on
average, one infected person transmits to 2-3 other people), the spread of virus by asymptomatic carriers
appears very inefficient and may have an R0<0.1 if this preliminary study is representative of
asymptomatic cases among other groups. Similar results were observed with SARS. Of 669 close
contacts to symptomatic SARS patients, 101 (15.1%) developed symptoms whereas when 363 others
had close contact to SARS patients during the incubation period (i.e. presymptomatic), none (0%)
developed symptoms11. Interestingly, most people are not effective at spreading COVID-19. A recent
study found that the distribution of individual R0 values was highly over-dispersed, with 80% of infections
being caused by ~9% of cases12. There are many factors that may impact transmission efficiency
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including duration of exposure, type of exposure/environment (indoor vs. outdoor, home vs. hospital,
public transportation, etc.), role and timing of social distancing interventions, and age/health status of the
infector as well as the infectee. Nevertheless, the various coronavirus studies described here indicate
that if we focus on one parameter of transmission (pre-symptom vs. post-symptom onset exposure), we
find that although presymptomatic transmission of COVID-19 is possible, it appears inefficient compared
to transmission after symptom onset.

A common issue with analysis of COVID-19 transmission rates is the lack of consistent data collection
and differences in symptom definitions. At a minimum, data collection should include symptoms such as
fever, cough, sore throat, shortness of breath/difficulty breathing, headache, muscle pain, recent loss of
taste or smell, and importantly, recollection of chills or night sweats since some individuals may not have
directly measured fever during acute symptom onset. Location of exposure (if known) should also be
documented when possible. One formidable challenge has been the lack of consensus on the definition
of fever in COVID-19. For instance, the Centers for Disease Control and Prevention (CDC) defines
COVID-19 fever as 38°C/100.4°F whereas fever was defined as 37.5°C/99.5°F in Wuhan, China13.
Thus, an infected individual with a temperature of 37.8°C/100.0°F would be considered asymptomatic in
one country and clearly symptomatic in the other. Even within the U.S., there is no consensus on the
definition for COVID-19 fever. States such as Georgia, Ohio, and Pennsylvania use a cutoff value of
38°C/100.4°F, Texas uses 37.8°C/100°F, and other states including Minnesota and Delaware use
37.5°C/99.5°F for routine temperature screening14. Although no single definition for fever will be perfect
in every circumstance, we propose using 37.5°C/99.5°F to increase the sensitivity for detecting mildly
symptomatic COVID-19 cases at the earliest stages of disease onset. Since transient spikes in body
temperature can occur for a variety of reasons (environment, physical exertion, etc.), specificity for
detecting fever may be increased by re-testing positive subjects after 20-30 minutes of acclimation to
confirm an elevated temperature if needed. In summary, coordinated development and standardization
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of clinical criteria among countries, and even between different states and clinical research groups, will
be necessary to reduce confusion in the field and improve the ability to compare and interpret COVID-19
study outcomes in the future.
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